XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Business Segment Information
12 Months Ended
Dec. 31, 2021
Business Segment Information  
Business Segment Information

Note 13.

Business Segment Information

The Company has one business activity and operates as one operating segment: the development and commercialization of ophthalmic therapies designed to treat glaucoma, corneal disorders and retinal diseases. The Company determined its operating segment on the same basis that it uses to evaluate its performance internally. The Company’s revenues disaggregated by revenue and product category are included in Note 7, Revenue from Contracts with Customers. The Company’s chief operating decision-maker, its Chief Executive Officer, reviews its consolidated operating results for the purpose of allocating resources and evaluating financial performance.

Property and equipment, net

Depreciation and amortization

Capital expenditures

As of December 31,

Year ended December 31,

Year ended December 31,

2021

2020

2019

2021

2020

2019

2021

2020

2019

    

    

United States

    

$

68,839

    

$

23,896

    

$

21,932

    

$

29,622

    

$

29,306

    

$

6,273

    

$

47,714

    

$

6,907

    

$

4,681

International

130

 

112

 

124

39

75

33

71

 

28

 

44

Total

 

$

68,969

$

24,008

$

22,056

$

29,661

$

29,381

$

6,306

$

47,785

$

6,935

$

4,725